Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Clin Cancer Res. Author manuscript; available in PMC 2010 August 1.
Published in final edited form as:
PMCID: PMC2771629

2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells



Novel natural killer (NK) cell-directed strategies in cancer immunotherapy aim at specifically modulating the balance between NK cell receptor signals towards tumor-specific activation. The signaling lymphocyte activation molecule (SLAM)-related receptor 2B4 (CD244) is an important regulator of NK cell activation. We investigated whether 2B4-enhanced activation signals can redirect the cytolytic function of human NK cells to NK-cell resistant and autologous leukemia and tumor targets.

Experimental design

In vitro stimulated NK cells from healthy donors and pediatric leukemia patients were gene-modified with CD19 or GD2-specific chimeric receptors (CARs) containing either the T cell receptor ζ or 2B4 endodomain alone or combined.


Chimeric 2B4 signaling alone failed to induce IL-2 receptor upregulation and cytokine secretion but triggered a specific degranulation response. Integration of the 2B4 endodomain into TCRζ CARs significantly enhanced all aspects of the NK-cell activation response to antigen-expressing leukemia or neuroblastoma cells, including CD25 upregulation, secretion of IFN-γ and TNF-α, release of cytolytic granules and growth inhibition, and overcame NK cell resistance of autologous leukemia cells while maintaining antigen specificity.


These data indicate that the 2B4 receptor has a potent costimulatory effect in NK cells. Antigen-specific 2B4-ζ-expressing NK cells may be a powerful new tool for adoptive immunotherapy of leukemia and other malignancies.

Keywords: NK cells, costimulation, cellular immunotherapy, B cell malignancies, gene transfer


Besides antigen-specific cytotoxic T lymphocytes, cellular components of the innate immune system can contribute to immune surveillance of malignant cell growth. In particular, natural killer (NK) cells can eliminate abnormal cells without priming or sensitization(1). Their activity is determined by the balance of signals from inhibitory and activating NK cell receptors. Inhibitory receptors, e.g. killer immunoglobulin receptors (KIRs), interact with self major histocompatibility complex (MHC) class I antigens and protect normal cells from NK-cell attack. Many malignant cells express MHC class I antigens and are thus naturally resistant to lysis by autologous NK cells. Accordingly, the first clinical trials using adoptive transfer of autologous NK cells have failed to produce significant therapeutic effects(2;3). For these reasons, NK-cell based immunotherapies have mostly focused on the haploidentical hematopoietic stem cell transplantation (HSCT) setting, where KIR:MHC Class I mismatches between the donor and recipient were found by many investigators to contribute to the control of residual myeloid leukemia cells(4;5). Increasing awareness of the role of activating receptors in the recruitment of NK effector functions has motivated new efforts to target autologous malignancies. Indeed, engagement of activating NK-cell receptors by ligands expressed on tumor cells can overcome inhibitory signals and stimulate NK-cell responses even in the presence of autologous MHC class I(6;7). This mechanism is efficiently counteracted in many human tumors, where cells evade NK-cell mediated killing by shedding or intracellular retention of ligands for activating receptors(8). Furthermore, inhibitory cytokines secreted within the malignant microenvironment result in systemic downmodulation of either NK-cell receptors or their ligands in cancer patients, further contributing to NK cell resistance(9). Attempts at increasing the susceptibility of malignant cells to NK-cell mediated lysis have focused on modulating the balance between inhibitory and activating NK cell receptor signals using agonistic cytokines or drugs(6;10).

An alternative approach is the genetic modification of NK cells with chimeric receptors (CARs) that retarget cellular activation pathways to tumor surface antigens. Tumor-specific CARs were first established in T cells(11). They consist of an antibody-derived single chain Fv domain linked to a cytoplasmic signaling domain, generally derived from the T cell receptor (TCR) ζ chain, thereby redirecting T-cell effector function to a defined target antigen. Expression of ζ-based CARs in NK cell lines(12;13) and primary human NK cells(14;15) can indeed trigger powerful stimulatory signals, inducing cytolysis of otherwise NK-cell resistant tumor cell lines. In T cells, the CAR-mediated antitumor functionality was significantly enhanced when integrated costimulatory signaling components were provided(16), emphasizing the importance of considering the full activation requirements of the effector cell for optimal CAR design. The stimulatory needs for overcoming the inhibitory effects of autologous MHC recognition in NK cells have not yet been established in detail. However, evidence exists that the NK-cell activation response can be positively modulated by the combination of multiple (co)stimulating signals(17).

The signaling lymphocyte activation molecule (SLAM)-related receptor 2B4 (CD244) is an important immune regulator, mediating potent stimulatory and costimulatory signals in both T cells and NK cells(1820). Thus, 2B4 could potentially enhance signaling in NK cells retargeted to malignant cells. Using CD19+ B-cell precursor acute lymphoblastic leukemia (ALL) and neuroblastoma as models, we investigated the capacity of antigen-specific CARs with integrated 2B4 signaling components to overcome resistance of malignant cells against NK-cell lysis.


Cell lines

The packaging cell line Phoenix-ampho(21) was provided by Gary P. Nolan (Stanford, CA). FLYRD 18 (provided by E. Vanin, Houston, USA) is an amphotrophic retrovirus packaging cell line that provides viral recombinants with the RD114 envelope. REH and SUP-B15 (both from ATCC) are acute lymphoblastic leukemia cell lines, ML-2 (ATCC) is a human acute myelomonocytic leukemia cell line. JF (kindly provided by Malcolm K. Brenner, Houston, USA) is a human neuroblastoma cell line. K562 (ATCC) is a human erythroleukemia line that is sensitive to lysis by natural killer cells. The generation of the K562-mb15-41BBL stimulator cells was described previously(14).


All CD19-specific CARs contain the single-chain antibody domain (scFv) of the monoclonal antibody FMC-63(22). The gene fragment encoding the transmembrane and cytoplasmic domains of 2B4 was cloned by polymerase chain reaction (PCR) from cDNA obtained from peripheral blood mononuclear cells (PBMCs) of a healthy donor. To generate 19-2B4ζ, the 2B4 gene fragment was subcloned upstream of the cytoplasmic domain of the TCRζ gene while replacing the transmembrane domains of ζ. For 19-2B4, the entire ζ fragment was replaced by the transmembrane and cytoplasmic domains of 2B4. The same strategy was applied to generate 14.G2a-2B4ζ from the previously published, GD2-specific CAR 14.G2a-ζ(23). The truncated fragment t2B4 was generated by site directed mutagenesis as previously described by Eissmann et al.(24) by inserting a stop codon at base pair number 892 of wild-type human 2B4 where the A of the start codon is base pair number one. To generate 19-t2B4ζ, the truncated 2B4 gene fragment up to base pair number 891 was subcloned upstream of the cytoplasmic domain of the ζ gene. All CAR genes were subcloned into the AgeI and NotI sites of the retroviral vector SFG-IRES-GFP which was generated by M. P. by inserting the IRES-GFP expression cassette into the retroviral vector SFG(25) (provided by R. C. Mulligan, Cambridge, MA). A previously published construct with FMC-63 mAb-derived CD19-specificity, the transmembrane domain of CD8α and the intracellular domains of 4-1BB and CD3ζ(26) was used for comparative experiments.

Production of recombinant retrovirus

To generate stable retroviral producer cell lines, fresh retroviral supernatants collected from transiently transfected Phoenix ampho cells were used to infect the packaging cell line FLYRD18 by overnight incubation at 37°C in the presence of polybrene (4 μg/ml). Viral supernatants were generated on the resulting bulk producer cell line by adding Isocoves modified Dulbecco medium (IMDM; BioWhittaker) supplemented with 20% FCS. After 24 hours of incubation at 32°C, the supernatants were filtered through a 0.45 μm filter, and used to transduce the NK cells.

Expansion and transduction of human NK cells

Approval for using peripheral blood samples of both healthy donors and pediatric leukemia patients was obtained from the University of Muenster Ethical Board. PBMCs were incubated at 1×106/well in a 24-well tissue-culture plate in the presence of 40 IU/ml recombinant human IL-2 (rhIL-2) in RPMI 1640 and 10% FCS and stimulated once with 0.75×106 irradiated (120 Gy) K562-mb15-41BBL stimulator cells, as previously described(14). For retroviral transductions, the cells were transferred to 24-well non-tissue culture-treated plates coated with recombinant fibronectin fragment FN CH-296 (Retronectin, Takara Shuzo, Otsu, Japan) at 4 μg/cm2, and coincubated with viral supernatant for 48 hours, followed by expansion in the presence of rhIL-2 (40 IU/ml).

Flow cytometry

Transduction efficiencies with CD19 constructs were determined by flow cytometric identification of GFP-expressing cells. Surface expression of 14.G2a-ζ and 14.G2a-2B4ζ was analyzed by staining with a biotinylated goat anti-mouse antibody specific for IgG F(ab')2 fragment (Jackson ImmunoResearch, Cambridgeshire, UK) and secondary phycoerythrin (PE)-labeled streptavidin antibody (Becton Dickinson, San Jose, CA). For immunophenotyping, cells were stained with fluorescein-conjugated monoclonal antibodies directed against CD3, CD56, CD16 (Becton Dickinson, San Jose, CA), CD19, CD48 (Immunotools, Friesoythe, Germany), MHC I (Dako, Glostrup, Denmark), and CD244 (eBioscience, San Diego, CA) surface proteins. For each sample, 20,000 cells were analyzed with FACSCalibur and Cell Quest Software (Becton Dickinson, San Jose, CA). Upregulation of CD25 in response to interaction with tumor targets was determined by staining of stimulated NK cells with phycoerythrin (PE)-marked CD25 antibody (Becton Dickinson, San Jose, CA) and subsequent analysis of PE-positive cells within the GFP+ CD56+ CD3− gate.

Intracellular cytokine assay

NK cells were seeded at 1×106 cells per well in a 24-well plate and stimulated with 1×106 irradiated tumor target cells for 4 hours. Cytokine secretion was blocked with 10 μg brefeldin A (Sigma, Munich, Germany) per 2×106 cells for 2 hours. Permeabilization of the cells was performed using a proprietary solution (Becton Dickinson, San Jose, CA). Cells were stained with IFN-γ and TNF-α-specific antibodies according to the manufacturer's recommendations.

CD107a assay

The cytolytic ability of transduced NK cells was assessed by flow cytometric analysis of CD107a expression after 4 hour coincubation with various tumor cell targets at a 1:1 stimulator to responder ratio in the presence of PE-labeled CD107a antibody (Becton Dickinson, San Jose, CA). After one hour, 5 μl of 2 mM monensin (Sigma, Munich, Germany) was added. The NK cells were washed and stained with PE-Cy7-labeled anti-CD56 antibody, followed by analysis of PE-positive cells within the GFP+CD56+ gate.

Long-term cytotoxicity assays

To allow for quantification of cytotoxicity by the low numbers of transduced effector cells obtained after FACS purification from patient samples, sensitive 16-hour coincubation assays were used. Target cells (2×105) were seeded into 96-well U-bottom tissue-culture plates and incubated with NK cells at various effector-target (E/T) ratios. JF neuroblastoma cells were labeled with CFSE prior to coincubation. Transduced NK cells were purified by cell sorting based on either GFP expression or F(ab) positivity, using a FACS Vantage (Becton Dickinson, San Jose, CA) prior to incubation. Cells were harvested after 16 hours. The percentages of viable leukemia cells were determined by staining with PE-labeled CD19 antibody (ImmunoTools, Friesoythe, Germany), and viable JF cells were assessed by CFSE staining. To adequately consider the number of leukemia cells undergoing spontaneous apoptosis, the numbers of target cells recovered from cultures without NK cells were used as a reference.

Statistical analysis

The student T test was used to test for significance in each set of values, assuming equal variance. Mean values ± SD are given unless otherwise stated.


Expression of chimeric receptor genes in human NK cells

NK cells were selectively expanded from PBMCs using a previously reported method(14). Briefly, PBMCs were stimulated with irradiated K562 cells gene-modified to express membrane-bound IL-15 and 41BB ligand in the presence of low-dose (40 IU/ml) rhIL-2. Under these conditions, NK cells were selectively expanded from the peripheral blood of 5 healthy donors to 14–61-fold (mean 30±18-fold) after 10 days of culture, resulting in a relative increase of CD3-CD56+ NK cells to 76–95% (89.5±7.0%) within the stimulated bulk populations on day 10 (Figure 1A), while the proportions of CD3+ T cells on day 10 ranged between 3.3 and 26.2% (10.2±7.0%).

Figure 1
Expansion and immunophenotypes of NK cells cocultured with K562-mb15-41BBL cells

These data were reproduced using peripheral blood samples of four pediatric patients with CD19+ B-cell precursor leukemia who were in complete hematological remission of their disease during maintenance treatment or within the first year after therapy. While the starting numbers of NK cells in the patients were substantially lower than in the healthy donors (1–13%, mean 6±5%, vs. 15–19%, mean 17±1%), comparable expansion rates were obtained in 5 independent cell cultures (14–72-fold, mean 31±23-fold) (Figure 1A). The expanded cells coexpressed CD56 and CD16high, characteristic for a highly cytolytic, activated NK cell subpopulation. Both the 2B4 receptor (CD244) and its ligand (CD48) were detected at high densities on the cell surface (Figure 1B). Reduced 2B4 expression in NK cells has been suggested to play a role in tumor immune escape(27). In our patients, the surface expression densities of 2B4 were comparable to healthy donors both at the initiation of the cultures, with mean fluorescence intensities (MFIs) of 113±28 in patients vs. 117±50 in healthy donors. Stimulation and expansion resulted in 2B4 upregulation in NK cells from both donor populations, resulting in MFIs of 201±140 in patients and 315±149 in healthy donors on day 10 (difference not statistically significant).

To compare the capacity of ζ and 2B4 for inducing functional antileukemia responses in NK cells, we generated CARs with identical extracellular specificity for the B-cell lineage antigen CD19 combined with various intracellular signaling domains (Figure 2). In CD19-ζ, which was previously described by our group and by others(14;22;28;29), the cytoplasmic signaling domain is derived from the ζ chain and thus contains three immunoreceptor tyrosine-based activation motifs (ITAMs). CD19-2B4 provides signaling by the full 2B4 receptor cytoplasmic domain, containing four immunoreceptor tyrosine-based switch motifs (ITSMs). In CD19-2B4ζ, both endodomains are combined. Based on data demonstrating the inhibitory effect of the third ITSM of 2B4 and the lack of significant stimulatory capacity of the fourth(24), further CARs were generated containing 2B4 endodomains truncated after the second ITSM (CD19-t2B4, CD19-t2B4ζ). The IRES-linked GFP within the transgenes permits quantification of transduced cells based on GFP fluorescence. Retroviral transduction was performed on day 5 after initial stimulation with K562-mbIL15-41BBL. Flow cytometric analysis revealed comparable transduction efficiencies in NK cells transduced with the individual receptor genes (Figure 2). In detail, the percentages of GFP+ NK cells were 16.7±7.6% for CD19-ζ, 16.2±8.8% for CD19-2B4, 12.9±7.1% for CD19-t2B4, 24.0±7.4% for CD19-2B4ζ, and 18.0±8.4% for CD19-t2B4ζ. The phenotype of the NK cells, as described above, was not affected by modification with CAR genes. Subsequent to transduction, NK cells could be kept in culture for at least 21–28 days without further stimulation. These results confirm that human NK cells from both healthy donors and pediatric leukemia patients can be efficiently expanded and gene-modified to express leukemia antigen-specific chimeric receptors15.

Figure 2
NK cells expanded from peripheral blood mononuclear cells are efficiently transduced with the CAR genes

CD19-induced 2B4 signaling costimulates specific NK cell activation

Functional NK cell activation responses are characterized by upregulation of the IL-2R (CD25) as well as production of cytokines and secretion of cytolytic granules, resulting in the specific cytolysis of target cells. To compare the capacity of the various CARs for inducing anti-leukemic NK-cell responses, we analyzed these parameters in response to interaction of gene-modified NK cells with antigen-expressing leukemia targets. In all flow cytometry-based assays, non-NK lymphocytes and nontransduced NK cells within the cultures were excluded from analysis by gating on GFP/CD56-coexpressing cells, and in direct cytolysis assays, the cells were purified by FACS for GFP expression. To adequately consider potential KIR-mediated interactions or natural engagements of the 2B4 receptor naturally expressed at high densities on the expanded NK cells (Figure 1B), MHC class I and CD48 expression was determined on all target cell lines. K-562 cells expressed low levels of MHC class I, in agreement with the previous observation that interactions between HLA-C molecules on K-562 cells and the CD160 NK-cell activating receptor contribute to their susceptibility to NK-cell lysis(30). REH and ML-2 leukemia cell lines were MHC class I positive. While CD48 was reported to be downregulated on most leukemias(7), we detected CD48 surface expression on both REH and ML-2 leukemia cell lines, but not on K562 (Figure 3A) and SupB15 cells (not shown).

Figure 3
CAR transduced NK cells functionally interact with antigen-expressing tumor targets

While exposure of CD19-ζ-transduced NK cells to CD19+ B-cell precursor ALL cell lines resulted in significant upregulation of CD25 (Figure 3B) as well as intracellular secretion of both IFN-γ and TNFα (Figure 3C) compared to non-transduced NK cells, the signal mediated by the CD19-2B4 receptor failed to induce either CD25 upregulation or cytokine secretion (Figure 3B, C). Elimination of the potentially inhibitory components of the 2B4 receptor endodomain in the truncated variant did not increase the activation response to the leukemia targets (Figure 3B, C). By contrast, a significant stimulatory effect of 2B4 became apparent in the receptor combining both signaling domains: Compared to ζ chain alone, 2B4ζ potently increased the specific NK cell response to CD19+ leukemia cells in both assay systems. The CD25 upregulation response to 2B4ζ was comparable to that observed with a previously described 4-1BB-signal enhanced CAR (Figure 3B). Importantly, the activation responses of transduced NK-cell cultures towards K562 were not affected by CAR expression (Figure 3B, C). Cells within the GFP-negative subpopulations of transduced NK cells failed to functionally interact with target cells, confirming that GFP is a prerequisite for antigen-specific functionality and thus provides an adequate surrogate parameter for CAR expression of transduced NK cells (not shown). The specificity of the transduced NK cell populations for the CAR-determined target antigen was confirmed by the lack of response to the CD19-negative cell line ML-2. Despite their high 2B4 receptor expression (Figure 1B), nontransduced NK cells failed to functionally interact with the CD48-expressing leukemic targets REH and ML-2 (Figure 3), although the relatively low expression of CD48 on these two targets does not allow any conclusions regarding potential NK-cell activation in response to high levels of surface CD48. In summary, while the capacity of 2B4 signaling alone in the absence of the ζ chain to mediate NK cell activation is clearly limited, 2B4 significantly costimulates the functional response to ζ-mediated signals.

2B4 signaling augments cytolytic NK-cell responses to leukemia cells

NK cells expressing a CD19-ζ CAR exert potent cytolytic responses against CD19-expressing leukemia target cells (Figure 4A). Engagement of the receptor CD19-2B4 also triggered a significant CD19-specific degranulation response, which was further enhanced with the truncated 2B4 receptor chain (CD19-t2B4). Thus, while 2B4 triggering in the absence of additional signals fails to induce full NK-cell activation (Figure 3), the signal mediated by the 2B4 cytoplasmic domain is sufficient for inducing an antigen-specific NK-cell degranulation response. Consistent with the synergistic capacity of 2B4 and ζ to induce cytokine secretion and CD25 upregulation, both combinations of the ζ chain with the full or truncated 2B4 endodomain resulted in a significantly enhanced potency of the degranulation response against CD19+ leukemia targets. When used in combination with TCRζ, truncated 2B4 was not consistently superior to the non-truncated domain, and the truncation even reduced the capacity of the combined receptor to induce CD25 upregulation. Again, the antigen specificity of the response was preserved in the presence of the 2B4 signal, as demonstrated by the lack of any significant background degranulation of the transduced NK cells in response to antigen-negative target cells (ML-2). Furthermore, all transduced NK-cell populations maintained vigorous degranulation responses towards K562 cells (Figure 4A). The enhancement of CD19-specific target cytolysis by 2B4 was further reflected by an increased potency of NK cells transduced with CD19-2B4ζ or CD19-t2B4ζ versus CD19ζ alone to significantly and specifically inhibit the lysis of cocultured REH cells (Figure 4B). Direct comparison with the 4-1BB-containing CAR demonstrated equal performance of the signal-enhanced CARs (Figure 4B). Altogether, these data demonstrate that 2B4 has both stimulatory as well as potent costimulatory effects on NK cytolytic responses against leukemia targets.

Figure 4
CAR transduced NK cells show powerful cytolytic responses against antigen-expressing tumor targets

CAR gene-modified NK cells efficiently lyse autologous leukemia cells

An important question with regard to the potential clinical application of this strategy regards the susceptibility of autologous leukemia cells to the cytolytic effects of natural or gene-modified NK cells. To address this issue, bone marrow leukemia cells obtained at diagnosis from two pediatric patients with CD19+ B-cell precursor cell ALL were cocultured with in vitro activated autologous NK cells in three independent experiments. The functionality of patient-derived NK cells was confirmed by their efficient degranulation response to K562 target cells. Non-transduced NK cells failed to exert degranulation (Figure 5A) and cytolytic (Figure 5B) responses against autologous leukemia cells and lysis of leukemia cells. Thus, the stimulatory signal induced by natural ligation of the 2B4 receptor in activated NK cells is insufficient for overcoming resistance in our model. While signaling via the ζ chain mediated significant lysis of autologous leukemic cells in the presence of transduced NK cells, it failed to induce a degranulation response to autologous targets, revealing an important lack of potency of the CD19-ζ receptor. By contrast, potent enhancement of both NK cell-degranulation as well as cytolysis was obtained by combined 2B4 and ζ signaling even in the autologous setting. Thus, retargeted 2B4 signaling can overcome resistance of autologous leukemia cells to NK-cell mediated cytolysis and potentiate NK-cell responses induced by a primary activation signal.

Figure 5
NK cells obtained from pediatric leukemia patients and gene-modified with CARs are highly cytolytic against autologous leukemia cell lines

2B4 signaling enhances NK-cell activation responses to neuroblastoma cells

To extend our findings to a solid tumor model, we investigated whether 2B4 signal-enhanced CARs may retarget NK cells to NK-cell resistant neuroblastoma cells. Neuroblastoma is the most common extracranial solid tumor of childhood. While many neuroblastoma cell lines have been shown to be susceptible to NK-cell mediated lysis, patient-derived primary neuroblastoma cells were considerably more resistant(31). We genetically modified four NK cell lines generated from three healthy donors with CARs containing the extracellular scFv domain of the GD2-specific monoclonal antibody 14.G2a and endodomains of either the TCRζ alone or in combination with 2B4. In contrast to the CD19-specific CARs, 14.G2a CARs are detectable on the cell surface by staining with Fab-specific antibody, allowing for the direct assessment of transgene expression. Transduction with 14.G2a-ζ and 14.G2a-2B4ζ resulted in surface expression on 51.9±12.6% and 11.2±9.3% of NK cells, respectively, confirming the proper assembly and transport of both ζ and 2B4ζ CARs to the cell surface (Figure 6A). Genetic modification with 14.G2a-2B4ζ, but not 14.G2a-ζ significantly enhanced the activation response of NK cells to the neuroblastoma cell line JF (Figure 6B). Furthermore, while JF cells were susceptible to lysis by two of three unmodified NK-cell cultures, resistance to the third NK cell line was successfully overcome by the signal-enhanced receptor (Figure 6C).

Figure 6
14.G2a-2B4ζ expression in NK cells enhances the activation response to GD2+ neuroblastoma cells and can overome their resistance to NK cell lysis


The first promising NK-cell based therapeutic strategies have been based on NK-alloreactivity between leukemia patients and their donors(4;5). Targeted activation of NK cells may establish immune control of autologous malignancies and thus extend the use of NK-cell therapies beyond the mismatched allotransplantation context. We present a strategy that allows to specifically and efficiently redirect NK cell effector functions to autologous leukemia cells via activating signaling pathways, overcoming their natural NK-cell resistance.

The concept of redirecting non-MHC restricted immune effector function towards tumor cells by genetic engineering with antigen-specific CARs has been widely studied in T cells(11) and has now entered the first clinical trials(3235). More recently, the potential of CARs was explored in cells of the innate immune system, including natural killer T (NKT) cells(36) and γδ T cells(22). Even though NK cells lack a TCR and thus fail to express a TCR-associated ζ chain, ζ is expressed in association with CD16(37), and engineered ζ signaling was shown to induce functional responses in the NK cell line NK-92(13) as well as in primary human NK cells(14;15). Our data confirm that triggering of ζ in NK cells induces a potent and antigen-specific activation response to allogeneic targets that overcomes inhibitory signals which otherwise prevent lysis of tumor target cells by unmodified allogeneic NK cells. However, in response to autologous leukemia targets, the CD19ζ-mediated NK-cell response was limited, and more potent receptors will likely be needed for eradication of residual disease in vivo.

“Second generation” receptors with integrated costimulatory signaling have substantially enhanced the redirected functionality of T cells against tumor targets(16;29). Activation responses of NK cells can also be amplified by coengagement of receptors with stimulatory properties(17). Indeed, the signaling domain of 4-1BB, a molecule with known costimulatory function in T cells, was shown to contribute to ζ-mediated NK cell activation responses to leukemia cells(14). Adjusting the cytoplasmic components of CARs to the specific activation requirements of NK cells is likely to maximize the outcome of their interaction with the tumor target cell. We chose the NK-cell receptor 2B4 (CD244) as a signal amplifyer of leukemia-specific activation responses, based on the following considerations. First, 2B4-induced signaling pathways is important in both innate and adaptive immune control as shown by the fatal immune dysfunction in patients with X-linked lymphoproliferative disease (XLP), who have genetic deficiencies in a molecule involved in 2B4 signaling(38). Second, engagement of 2B4 on NK cells by its ligand CD48 is critical for optimal NK-cell function(39), and potently enhances activation induced by other NK receptors(40). Finally, a role for 2B4 in tumor immunity was suggested by its contribution to eliminating tumor cells in mice(19), and by the association of reduced 2B4 expression in NK cells from multiple myeloma patients with tumor immune escape(41). We found that integrated signals from 2B4 combined with ζ significantly enhance all aspects of the NK-cell activation response, including CD25 upregulation, secretion of IFN-γ and TNF-α, release of cytolytic granules and target-specific growth inhibition. Importantly, integration of 2B4 efficiently overcame the limited activation response to autologous leukemia target cells induced by CD19ζ. The antigen specificity of the interaction was fully preserved, ruling out autoproliferation and promiscuity of killing as a potential consequence of signal leakage by the multiple signaling components of the receptor. Furthermore, the capacity of gene-modified NK cells to functionally respond to K562 cells was fully maintained. Compared to the previously described 4-1BB signal enhanced CAR(14), the functional assays did not reveal superiority of either construct. However, beyond in vitro functionality, the costimulatory signal provided by the CAR is highly likely to affect the in vivo performance of gene-modified NK cells, regarding antitumor activity, robustness of cytokine and cytolytic responses, and persistence in vivo. Only clinical trials can demonstrate which of the available second-generation CARs has the highest potential of inducing sustained antitumor NK-cell responses. In summary, CD19-2B4ζ is a novel CAR with improved signaling characteristics for mediating powerful and specific antileukemic NK cell effector functions and efficiently breaking resistance to autologous NK cell lysis.

Besides their potential in anticancer immunotherapy, CARs are an excellent tool for identifying the functional consequences of receptor triggering in individual cell populations. To this end, our findings might help elucidating open questions regarding the role of 2B4 in NK cells. It is still controversial whether activation by 2B4 is strong enough to break NK-cell tolerance in the presence of KIR signals, and some investigators have even reported 2B4 to provide inhibitory signals(42;43). Indirect evidence against a dominant stimulatory role of 2B4 in NK cells is the broad expression of its ligand CD48 on all nucleated hematopoietic cells. We found that natural interactions between CD48 and 2B4 on activated NK cells failed to overcome resistance of leukemia cells to NK-cell mediated cytolysis. Furthermore, assessment of the direct consequences of enforced 2B4 signaling via CARs revealed an incomplete activation responses to 2B4 with an inferior functional outcome compared to ζ triggering. Thus, 2B4 emerges from these experiments as a receptor with weak stimulatory and potent costimulatory function, exerting its full potential in human NK cells in combination with additional activating signals.

As a member of the SLAM family, the cytoplasmic tail of 2B4 contains 4 ITSMs(18). While phosphorylation of the first and second ITSMs result in activation of stimulatory downstream pathways, the third motif was suggested to have a negative influence on human NK cell activation(44). However, in our system, the truncation did not consistently improve the functionality of the gene-modified T cells, and even had a negative effect on antigen-specific CD25 upregulation. While we can only speculate about the potential reasons, it is conceivable that NK-cell activation prior to expansion and transduction with 2B4-containing constructs may have overcome the inhibitory effect of the third ITSM by upregulating cellular SAP expression, which was shown to positively modulate 2B4 function(45;46).

One obvious potential clinical application of CAR gene-modified NK cells is the prevention of leukemia relapse following hematopoietic stem cell transplantation (HSCT) in high risk patients. In contrast to existing NK-cell based strategies, fully matched related and unrelated donors can be used regardless of KIR typing. We further propose that autologous 2B4ζ gene-modified NK cells may efficiently target minimal residual leukemia cells after conventional chemotherapy or high-dose therapy. Besides hematological diseases requiring allogeneic transplantation, genetic manipulation of NK cells allows to extend their use to various other cancers, since CARs with various specificities have been generated in previous years. Using neuroblastoma as an example, we demonstrated that 2B4ζ CAR gene-modified NK cells receive potent activation stimuli by antigen-expressing tumor cells and are capable of overcoming resistance of an individual neuroblastoma cell line to NK-cell cytolysis. Critical aspects for the clinical translation of CD19-2B4ζ redirected NK cells regard the feasibility and safety of the approach as well as factors ensuring maximum efficacy. We confirmed that despite the immunosuppressed state of pediatric patients during cytostatic maintenance therapy for leukemia, NK cells with a highly cytolytic, activated phenotype can be expanded and gene-modified with comparable efficiencies to healthy donors. GMP-compliant protocols for the large-scale in vitro expansion of human NK cells have been developed(47;48). While alloreactive residual T cells may have to be removed from bulk cultures of expanded NK cells by clinical-grade sorting strategies in the mismatched allogeneic setting, enriched cultures of autologous, retargeted NK cells can be used adoptive immunotherapy without further selection.

A key issue regarding long-term control of leukemia is the in vivo persistence of the transferred effector cell populations. While haploidentical donor NK-cell infusions have indeed resulted in persistence and expansion of NK cells in vivo(4), concomitant administration of IL-2 will likely be required to explore the full potential of 2B4ζ-gene-modified NK cells to survive in vivo. Comparable to T-cell based strategies, embedding of 2B4ζ-transduced NK cell transfusions in a clinical context of preceding depletion of regulatory T cells and maximum cytoreduction may further enhance their therapeutic potential.

Statement of translational relevance

In recent years, NK cell strategies for cancer immunotherapy have stimulated increasing interest but their clinical application has largely been restricted to the haploidentical hematopoietic stem cell transplantation (HSCT) setting, where natural KIR-mismatches between the donor and recipient are exploited to enhance the graft-anti-leukemia effect. In this paper, we describe a gene-engineering strategy that efficiently modulates the balance of human NK cell signals towards tumor-specific activation. This strategy promises to extend the use of NK cells in cancer therapy beyond allogeneic mismatched HSCT. Due to the high selectivity of the gene-modified NK cells for their tumor targets, NK cells from fully matched donors as well as autologous NK cells can be used. Our data thus pave the way towards the clinical application of NK cells for the efficient and specific elimination of minimal residual tumor cells in various malignancies.


Financial support This work was supported by a grant from the Dr. Mildred-Scheel-Stiftung der Deutschen Krebshilfe (to C.R.) and EU funding provided for the “CHILDHOPE” network program under the terms of an EU Framework 6 grant (to C.R. and M.P.).

Reference List

1. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:2731–2736. [PubMed]
2. Burns LJ, Weisdorf DJ, Defor TE, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplantation. 2003;32:177–186. [PubMed]
3. Lister J, Rybka WB, Donnenberg AD, et al. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clinical Cancer Research. 1995;1:607–614. [PubMed]
4. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–3057. [PubMed]
5. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100. [PubMed]
6. Kim JY, Bae JH, Lee SH, et al. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide. Journal of Immunotherapy. 2008;31:475–486. [PubMed]
7. Pende D, Spaggiari GM, Marcenaro S, et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112) Blood. 2005;105:1066–2073. [PubMed]
8. Romanski A, Bug G, Becker S, et al. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Experimental Hematology. 2005;33:344–352. [PubMed]
9. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. Journal of Immunology. 2004;172:7335–7340. [PubMed]
10. Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leukemia Research. 2007;31:1393–1402. [PubMed]
11. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90:720–724. [PubMed]
12. Muller T, Uherek C, Maki G, et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunology Immunotherapy. 2008;57:411–423. [PubMed]
13. Uherek C, Tonn T, Uherek B, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100:1265–1273. [PubMed]
14. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106:376–383. [PubMed]
15. Kruschinski A, Moosmann A, Poschke I, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci USA. 2008;105:17481–17486. [PubMed]
16. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nature Biotechnology. 2002;20:70–75. [PubMed]
17. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107:159–166. [PubMed]
18. Garniwagner BA, Purohit A, Mathew PA, Bennett M, Kumar VA. Novel Function-Associated Molecule Related to Non-Mhc-Restricted Cytotoxicity Mediated by Activated Natural-Killer-Cells and T-Cells. J Immunol. 1993;151:60–70. [PubMed]
19. Lee KM, Forman JP, McNerney ME, et al. Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood. 2006;107:3181–3188. [PubMed]
20. Valiante NM, Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. Journal of Experimental Medicine. 1993;178:1397–1406. [PMC free article] [PubMed]
21. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Human Gene Therapy. 1996;7:1405–1413. [PubMed]
22. Rischer M, Pscherer S, Duwe S, et al. Human gamma delta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. British Journal of Haematology. 2004;126:583–592. [PubMed]
23. Rossig C, Bollard CM, Nuchtern JG, et al. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. International Journal of Cancer. 2001;94:228–236. [PubMed]
24. Eissmann P, Beauchamp L, Wooters J, et al. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244) Blood. 2005;105:4722–4729. [PubMed]
25. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:6733–6737. [PubMed]
26. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18:676–684. [PubMed]
27. Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia. 2006;20:732–733. [PubMed]
28. Cooper LJN, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. 2003;101:1637–1644. [PubMed]
29. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical Cancer Research. 2007;13:5426–5435. [PubMed]
30. Le Bouteiller P, Barakonyi A, Giustiniani J, et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci USA. 2002;99:16963–16968. [PubMed]
31. Castriconi R, Dondero A, Corrias MV, et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Research. 2004;64:9180–9184. [PubMed]
32. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research. 2006;12:6106–6115. [PMC free article] [PubMed]
33. Lamers CHJ, Langeveld SCL, Ruijven CMGV, Debets R, Sleijfer S, Gratama JW. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunology Immunotherapy. 2007;56:1875–1883. [PubMed]
34. Park JR, DiGiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Molecular Therapy. 2007;15:825–833. [PubMed]
35. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261–2271. [PubMed]
36. Pieper M, Scheffold C, Duwe S, et al. Immunotherapy of B-cell malignancies with genetically engineered human CD8(+) natural killer T cells. Leukemia. 2006;20:729–732. [PubMed]
37. Geertsma MF, Stevenhagen A, van Dam EM, Nibbering PH. Expression of zeta molecules is decreased in NK cells from HIV-infected patients. FEMS Immunology and Medical Microbiology. 1999;26:249–257. [PubMed]
38. Benoit L, Wang X, Pabst HF, Dutz J, Tan R. Defective NK cell activation in X-linked lymphoproliferative disease. Journal of Immunology. 2000;165:3549–3553. [PubMed]
39. Nakajima H, Cella M, Langen H, Friedlein A, Colonna M. Activating interactions in human NK cell recognition: the role of 2B4-CD48. European Journal of Immunology. 1999;29:1676–1683. [PubMed]
40. Sivori S, Parolini S, Falco M, et al. 2B4 functions as a co-receptor in human NK cell activation. European Journal of Immunology. 2000;30:787–793. [PubMed]
41. Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia. 2006;20:732–733. [PubMed]
42. Lee KM, McNerney ME, Stepp SE, et al. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. Journal of Experimental Medicine. 2004;199:1245–1254. [PMC free article] [PubMed]
43. Vacca P, Pietra G, Falco M, et al. Analysis of natural killer cells isolated from human decidua: Evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK-cell function. Blood. 2006;108:4078–4085. [PubMed]
44. Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244) Blood. 2005;105:4722–4729. [PubMed]
45. Chlewicki LK, Velikovsky CA, Balakrishnan V, et al. Molecular basis of the dual functions of 2B4 (CD244) J Immunol. 2008;180:8159–8167. [PubMed]
46. Endt J, Eissmann P, Hoffmann SC, et al. Modulation of 2B4 (CD244) activity and regulated SAP expression in human NK cells. Eur J Immunol. 2007;37:193–198. [PubMed]
47. Alici E, Sutlu T, Bojrkstrand B, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111:3155–3162. [PubMed]
48. Koehl U, Sorensen J, Esser R, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004;33:261–266. [PubMed]